Outlook For Reata's Bardoxolone Improves With Phase II Updates
Latest data support moving bardoxolone into Phase III for autosomal dominant polycystic kidney disease (ADPKD).
You may also be interested in...
Once suspended due to safety issues, bardoxolone now has completed a Phase II study that showed kidney function benefit in four rare types of CKD. A pivotal study is underway, with another planned and more possible.
Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.